Second drug targeting KRASG12C shows benefit in mutated non-small-cell lung cancer
Source :
https://www.eurekalert.org/pub_releases/2021-03/esfm-sdt032321.phpClinical activity with a second drug inhibiting KRASG12C confirms its role as a therapeutic target in patients with advanced non-small-cell lung cancer (NSCLC) harbouring this mutation, according to results from a study with the KRASG12C inhibitor adagrasib reported at the European Lung Cancer Virtual Congress 2021.